Genmab Announces US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Genmab A/S
17.11.2011 09:18
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- US Court enters judgment that Arzerra does not infringe Genentech and Biogen
Idec US patent covering methods of treating CLL with anti-CD20 antibodies
Copenhagen, Denmark; November 17, 2011 - Genmab A/S (OMX: GEN) announced today
that a US District Court entered final judgment in favour of GlaxoSmithKline
(GSK) in a patent infringement case involving Arzerra brought against GSK by
Genentech and Biogen Idec.
Genentech and Biogen Idec filed the patent infringement lawsuit in Q1 2010 with
the US District Court in San Diego, California claiming Arzerra infringed US
Patent No 7,682,612 covering methods of treating Chronic Lymphocytic Leukemia
(CLL) with anti-CD20 antibodies. GSK denied infringement and claimed the patent
was invalid and unenforceable.
The decision in favour of GSK came after the court defined certain terms of the
patent claims. Based on this Genentech and Biogen Idec conceded to a judgment
in favour of GSK's counterclaim of non-infringement. Genentech and Biogen Idec
will have the option to appeal the decision concerning the interpretation of
the patent claims.
Arzerra, Genmab's anti-CD20 antibody, is partnered with GSK and marketed in the
US and Europe for the treatment of fludarabine and alemtuzumab refractory CLL.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 31
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=369009
News Source: NASDAQ OMX
17.11.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Genmab A/S
17.11.2011 09:18
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- US Court enters judgment that Arzerra does not infringe Genentech and Biogen
Idec US patent covering methods of treating CLL with anti-CD20 antibodies
Copenhagen, Denmark; November 17, 2011 - Genmab A/S (OMX: GEN) announced today
that a US District Court entered final judgment in favour of GlaxoSmithKline
(GSK) in a patent infringement case involving Arzerra brought against GSK by
Genentech and Biogen Idec.
Genentech and Biogen Idec filed the patent infringement lawsuit in Q1 2010 with
the US District Court in San Diego, California claiming Arzerra infringed US
Patent No 7,682,612 covering methods of treating Chronic Lymphocytic Leukemia
(CLL) with anti-CD20 antibodies. GSK denied infringement and claimed the patent
was invalid and unenforceable.
The decision in favour of GSK came after the court defined certain terms of the
patent claims. Based on this Genentech and Biogen Idec conceded to a judgment
in favour of GSK's counterclaim of non-infringement. Genentech and Biogen Idec
will have the option to appeal the decision concerning the interpretation of
the patent claims.
Arzerra, Genmab's anti-CD20 antibody, is partnered with GSK and marketed in the
US and Europe for the treatment of fludarabine and alemtuzumab refractory CLL.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 31
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=369009
News Source: NASDAQ OMX
17.11.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------